TCW Group’s Amicus Therapeutics FOLD Stock Holding History

TCW Group’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-15,671	Closed	-$245K	–	337
2018 Q2	$245K	Buy	+15,671	New	+$237K	﹤0.01%	332

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

TCW Group's FOLD Position: Q3 2018 in Review

TCW Group sold out of Amicus Therapeutics (FOLD) in Q3 2018, closing a stake of 15,671 shares — an estimated $245K sold.

TCW Group first reported a position in FOLD in Q2 2018 and held it in 1 quarter. The position peaked at $245K in Q2 2018. 204 funds tracked by Wall St. Rank hold FOLD as of Q3 2018.

TCW Group reported no remaining Amicus Therapeutics position as of Q3 2018 after selling out during the quarter.
TCW Group sold 15,671 Amicus Therapeutics shares in Q3 2018, an estimated $245K.
TCW Group first reported a position in Amicus Therapeutics in Q2 2018 and held it in 1 quarter.
TCW Group's Amicus Therapeutics position peaked at $245K in Q2 2018.
204 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2018.

Based on TCW Group's 13F filing for Q3 2018, filed 30 Oct 2018.